Summary & Overview
CPT 87501: Influenza Virus Nucleic Acid Detection (RT-Amplified Probe)
CPT code 87501 designates a molecular diagnostic assay that detects influenza virus RNA by nucleic acid methods, including reverse transcription and amplified probe techniques, reported per type or subtype. This code reflects the laboratory confirmation of influenza infection, a nationally important public health and clinical diagnostic service that supports treatment decisions, infection control, and surveillance. Coverage and reimbursement for molecular influenza testing influence laboratory workflow, test adoption, and access to timely diagnostics across clinical settings.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication reviews payer coverage patterns, reimbursement benchmarks, and relevant clinical context for molecular influenza testing.
Readers will find: benchmarked reimbursement ranges and typical payment practices across major payers; a concise clinical overview of the test purpose and common sites of service; and policy and billing considerations affecting laboratory reporting and claim submission. The content summarizes what stakeholders need to know about CPT code 87501 for operational planning, billing accuracy, and aligning clinical laboratory services with payer requirements. Data not available in the input will be explicitly noted where applicable.
Billing Code Overview
CPT code 87501 describes a laboratory test that detects the presence of influenza virus using nucleic acid detection methods, including reverse transcription and amplified probe technique, reported for each type or subtype. The procedure is a molecular diagnostic assay performed by a laboratory analyst to identify influenza A, influenza B, or specific subtypes when applicable.
Service Type
- Molecular diagnostic testing (nucleic acid amplification test for influenza).
Typical Site of Service
- Clinical laboratory or hospital laboratory; testing may also be performed in certified outpatient laboratory facilities or other licensed diagnostic laboratories.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual presenting to an urgent care clinic, emergency department, primary care office, or hospital laboratory during influenza season with acute respiratory symptoms such as fever, cough, sore throat, myalgias, and nasal congestion. A clinician collects a nasopharyngeal or nasal swab specimen and sends it to the clinical laboratory for nucleic acid amplification testing (NAAT) with reverse transcription to detect influenza A and B viral RNA and, when available, subtyping. The laboratory analyst performs 87501, which uses reverse transcription and amplified probe techniques to identify the presence of influenza virus RNA for each type or subtype. Results typically return within hours to inform antiviral therapy decisions, infection control measures, and public health reporting. Common workflow steps include specimen collection, accessioning, RNA extraction, reverse transcription, amplification and detection, result verification by a qualified technologist, and transmission of results to the ordering provider and the electronic health record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; not typically applied to laboratory services but present in raw modifier lists |